
Cencora, Inc. company profile
$356.94−0.58%Close 16 Nov 2026 · Market value $67.23B
About Cencora, Inc.
Cencora is a global pharmaceutical sourcing and distribution services company serving healthcare providers and pharmaceutical and biotech manufacturers in the United States and select global markets, as well as in human and animal health. It distributes brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipment to customers including acute care hospitals, health systems, retail and mail order pharmacies, medical and dialysis clinics, physician practices, and veterinarians. It also provides services such as data analytics, reimbursement and pharmaceutical consulting, specialty logistics, inventory management, pharmacy automation, and packaging solutions. Its operations are organized into U.S. Healthcare Solutions and International Healthcare Solutions, with the international segment operating primarily in Europe and Canada.
A summary of the business section of the company's latest annual report, filed 25 Nov 2025.
Company facts
| Ticker | COR · NYSE |
|---|
| Sector | Distribution |
|---|
| Industry | Health Care Distributors |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 30 September |
|---|
| Reporting currency | USD |
|---|
| CIK | 1140859 |
|---|
| Latest annual report | 10-K, filed 25 Nov 2025 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Steven H. Collis | Former Executive Chairman and Director | 381K · < 1% | Option exercise, 16 Sep 2025 |
|---|
| James F. Cleary | Executive Vice President and Chief Financial Officer | 146K · < 1% | Option exercise, 11 Mar 2026 |
|---|
| Robert P. Mauch | President, Chief Executive Officer and Director | 115K · < 1% | Option exercise, 12 Nov 2026 |
|---|
| Elizabeth S. Campbell | Executive Vice President and Chief Legal Officer | 27.2K · < 1% | Option exercise, 12 Nov 2026 |
|---|
| D. Mark Durcan | Director | 21.9K · < 1% | Open-market purchase, 18 Jun 2026 |
|---|
| Silvana Battaglia | Executive Vice President and Chief Human Resources Officer | 20.5K · < 1% | Grant or award, 30 Jun 2026 |
|---|
| Lon R. Greenberg | Director | 17.1K · < 1% | Open-market sale, 16 Sep 2026 |
|---|
| Dennis M. Nally | Director | 12.7K · < 1% | Grant or award, 30 Oct 2026 |
|---|
| Redonda G. Miller, M.D. | Director | 1.6K · < 1% | Grant or award, 5 Mar 2026 |
|---|
| Lauren M. Tyler | Director | 426 · < 1% | Grant or award, 30 Oct 2026 |
|---|
| Frank K. Clyburn | Director | 378 · < 1% | Grant or award, 5 Mar 2026 |
|---|
| Lorence H. Kim, M.D. | Director | 168 · < 1% | Grant or award, 5 Mar 2026 |
|---|
| Verma Pawan | EVP, Chief Data & Info Officer | — | Option exercise, 12 Nov 2026 |
|---|
| Krikorian Lazarus | SVP & Chief Accounting Officer | — | Option exercise, 12 Nov 2026 |
|---|
| Ellen G. Cooper | Director | — | Grant or award, 30 Oct 2026 |
|---|
| SANCHEZ ROBERT E | Director | — | Grant or award, 1 Oct 2026 |
|---|
| Werner Baumann | Director | — | Grant or award, 5 Mar 2026 |
|---|
| Lori J. Ryerkerk | Director | — | Grant or award, 5 Mar 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
COR in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.